RNA Interference Technology Market by Type, Therapeutics, Application

Description

List of Tables

[195 Pages Report] The RNA Interference Technology Market size was estimated at USD 32.92 billion in 2023 and expected to reach USD 39.25 billion in 2024, at a CAGR 22.38% to reach USD 135.40 billion by 2030.

The RNA interference (RNAi) technology market encompasses systems that use small RNA molecules to regulate gene expression. This technology is applicable in functional genomics, therapeutic developments, and agriculture for pest control. It encompasses various related products such as reagents, siRNA, shRNA, and microRNA and services for RNAi-based research and development. The key factors influencing the growth of the RNAi technology market include advancements in gene therapy and the increasing prevalence of genetic disorders. Additionally, rising investments in drug discovery and development processes are driven by RNAi. While the RNAi technology market presents significant growth potential, there are notable limitations and challenges, including difficulty in delivering RNAi molecules effectively to targeted cells and ensuring their stability within the body. Risk of unintended gene silencing, leading to off-target effects and potential toxicity. However, advancements in gene therapy and the increasing prevalence of genetic disorders. Rising investments in drug discovery and development processes driven by RNAi.

KEY MARKET STATISTICS
Base Year [2023]	USD 32.92 billion
Estimated Year [2024]	USD 39.25 billion
Forecast Year [2030]	USD 135.40 billion
CAGR (%)	22.38%

Type: siRNA's use for targeted gene therapy for treating a multitude of diseases

dsRNA acts as the precursor molecule in the RNAi pathway and is recognized by the cell's machinery to be processed into smaller RNAi-effective molecules. It triggers a natural defense mechanism against RNA viruses and is used in various applications, including agricultural biotechnology and therapeutic developments. miRNA is a small non-coding RNA molecule found in plants, animals, and some viruses, which functions in RNA silencing and post-transcriptional regulation of gene expression. Research into miRNA has surged due to its role in regulating cellular functions and implications in various diseases, including cancer. siRNA is a class of double-stranded RNA molecules, typically 20-25 base pairs in length that interfere with the expression of specific genes with complementary nucleotide sequences. siRNA has been a focus area for drug development, notably in gene therapy, to target and silence genetic abnormalities at the mRNA level. dsRNA's stable nature and broad-spectrum activity make it favorable for agricultural use and the initial stages of viral defense research, while miRNA's role in gene regulation offers promise for complex disease therapy and diagnostics. siRNA's high specificity and reduced off-target effects position it as a frontrunner in targeted gene therapy for many diseases.

Application: Exponential adoption of RNA interference technology for dru discovery & development

The RNAi in drug discovery and development is primarily used to identify the function of genes and validate drug targets. RNAi allows researchers to efficiently silence genes in a reversible and highly specific manner, which facilitates identifying how particular genes contribute to disease. RNAi technology is applied directly to silence disease-causing genes in the therapeutics segment. This has led to the development of new medicines, particularly for diseases caused by single-gene mutations or where traditional small-molecule drugs or biologics have been ineffective. Therapeutic application of RNAi is preferred for diseases with known genetic bases, such as certain types of cancer, viral infections, and inherited genetic disorders.

Regional Insights

In the Americas, RNA interference (RNAi) technology has seen significant advancement, particularly within the biotechnology and pharmaceutical sectors. The United States leads in this space, with a strong presence of companies and research institutions driving innovation. Initiatives by the National Institutes of Health (NIH) and collaborations within RNAi-focused biotech hubs promote further research and development. Additionally, venture capital is increasingly funding startups that leverage RNAi for gene silencing in various medical applications, ranging from cancer therapy to genetic disorders. The EMEA region shows a diverse landscape for RNAi technology, with Europe taking the lead in clinical development and research. European biotech companies, such as Silence Therapeutics and CureVac in Germany, have been instrumental in advancing RNAi-based therapeutics. Moreover, the European Medicines Agency (EMA) provides a robust framework for RNAi drug approval, further facilitating growth in this domain. The biomedical research community, supported by funding from the European Union through various Framework Programmes, continues to contribute to the understanding and application of RNAi. Activity within the Middle East and African markets is emerging, with research primarily driven by academic institutions eager to bridge the technology gap and explore RNAi's potential in tackling region-specific diseases. The Asia-Pacific region demonstrates rapid growth in RNAi technology with a strong emphasis on innovation and market expansion. Japan and China are at the forefront of this growth due to their investments in biotechnology research and quickly evolving pharmaceutical sectors. Government initiatives and collaborations with international biotech firms have significantly contributed to the industry's growth, with academic research institutions providing foundational insights into RNAi mechanisms. Additionally, the region's increasing participation in global clinical trials exhibits a commitment to integrating RNAi therapeutics into their healthcare systems. This integration is facilitated by APAC's dynamic regulatory environment, striving to keep pace with the evolving scientific landscape.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the RNA Interference Technology Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the RNA Interference Technology Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the RNA Interference Technology Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., AMSBIO, Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Atalanta Therapeutics, Bioneer Corporation, CureVac N.V., Dicerna Pharmaceuticals, Inc., Gotham Therapeutics Corp., Gradalis, Inc., Ionis Pharmaceuticals, Inc., Merck KGaA, NeuBase Therapeutics, Inc., Novartis AG, Nutcracker Therapeutics, Inc., Phio Pharmaceuticals Corp., ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the RNA Interference Technology Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- dsRNA
- miRNA
- siRNA

Therapeutics
- Autoimmune Hepatitis
- Hepatitis B and C
- Neurological Disorders
- Oncology
- Respiratory Disorders

Application
- Drug Discovery and Development
- Therapeutics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the RNA Interference Technology Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the RNA Interference Technology Market?

3. What are the technology trends and regulatory frameworks in the RNA Interference Technology Market?

4. What is the market share of the leading vendors in the RNA Interference Technology Market?

5. Which modes and strategic moves are suitable for entering the RNA Interference Technology Market?

Product Code: MRR-0375F3EAA810

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising Prevalence of Genetic and Chronic Disorders Globally
  - 5.1.1.2. Increasing Application of RNAi Technology in Drug Discovery & Development
  - 5.1.1.3. Growing Need for Molecular Diagnostics
- 5.1.2. Restraints
  - 5.1.2.1. Stringent FDA Regulations Regarding RNAi Therapies
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing Research and Development in the Field of Nanotechnology and Cancer
  - 5.1.3.2. State-of-the-art RNAi Therapies in Development
- 5.1.4. Challenges
  - 5.1.4.1. Concerns in Delivery of RNA-Interference Therapies
5.2. Market Segmentation Analysis
- 5.2.1. Type: siRNA's use for targeted gene therapy for treating a multitude of diseases
- 5.2.2. Application: Exponential adoption of RNA interference technology for dru discovery & development
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. RNA Interference Technology Market, by Type

6.1. Introduction
6.2. dsRNA
6.3. miRNA
6.4. siRNA

7. RNA Interference Technology Market, by Therapeutics

7.1. Introduction
7.2. Autoimmune Hepatitis
7.3. Hepatitis B and C
7.4. Neurological Disorders
7.5. Oncology
7.6. Respiratory Disorders

8. RNA Interference Technology Market, by Application

8.1. Introduction
8.2. Drug Discovery and Development
8.3. Therapeutics

9. Americas RNA Interference Technology Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific RNA Interference Technology Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa RNA Interference Technology Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Switch Therapeutics Launches with USD 52 Million to Advance First-of-its-Kind RNAi Technology
- 12.3.2. Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio